QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2004

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware   0-26642   87-0494517
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


ITEM 2.02 Results of Operations and Financial Condition.

        On November 9, 2004, Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2004. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.


ITEM 9.01 Financial Statements and Exhibits.


Exhibit
Number
   Description
99.1   Earnings release dated November 9, 2004 for the three months ended September 30, 2004.

2


SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
MYRIAD GENETICS, INC.

Date: November 9, 2004
 
By:
 
/s/  PETER D. MELDRUM      
Peter D. Meldrum
President and Chief Executive Officer

3


EXHIBIT INDEX

Exhibit
Number
   Description
99.1   Earnings release dated November 9, 2004 for the three months ended September 30, 2004.



QuickLinks

SIGNATURES
EXHIBIT INDEX